Showing results (171-180 of 178) with videos related to
Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Molecular Oncology|April 10, 2022
Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinomaJuliette Mainguené, Sophie Vacher, Maud Kamal, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.Nature|August 2, 2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancerPhilippe A Cassier, Raul Navaridas, Melanie Bellina, et al.Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.Pageof 18